GlaxoSmithKline and XenoPort, Inc. announced today that the Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for postherpetic neuralgia (PHN) treatment in adults.
Home » » Postherpetic Neuralgia Treatment
Postherpetic Neuralgia Treatment
